Discover and read the best of Twitter Threads about #Lauras
Most recents (2)
A MEGA THREAD ON 📕
RETEST TRADING !
DO EVERY STOCK RETEST AFTER BREAKOUT ?WHEN TO TAKE AN ENTRY ?
WHICH IS BETTER ?
RETWEET AND LIKE ❤
@kuttrapali26
@rohanshah619
@Mr_Chartist @AmitabhJha3
RETEST TRADING !
DO EVERY STOCK RETEST AFTER BREAKOUT ?WHEN TO TAKE AN ENTRY ?
WHICH IS BETTER ?
RETWEET AND LIKE ❤
@kuttrapali26
@rohanshah619
@Mr_Chartist @AmitabhJha3
2/
What is RETEST ?
When a stock Breaks out of a range that is called a breakout point .
The resistance that it was facing should now act as support .
Retest means after the Resistance is broken the stock comes back to take support in that region
What is RETEST ?
When a stock Breaks out of a range that is called a breakout point .
The resistance that it was facing should now act as support .
Retest means after the Resistance is broken the stock comes back to take support in that region
3/
MAJORITY of time stock comes back to test the previous breakout region .
I have seen that 90% of The breakouts gets tested again !
And most REWARDING EXPERIENCE for me is during Retests only
MAJORITY of time stock comes back to test the previous breakout region .
I have seen that 90% of The breakouts gets tested again !
And most REWARDING EXPERIENCE for me is during Retests only
A thread on #Lauras lab stock
Company is mainly into 3 business segment
1. Generic API
2. Formulations
3. Synthesis (CDMO)
let's focus on risk & opportunity in each segment rather than focusing on number which are known to us.
.
(1/11)
Company is mainly into 3 business segment
1. Generic API
2. Formulations
3. Synthesis (CDMO)
let's focus on risk & opportunity in each segment rather than focusing on number which are known to us.
.
(1/11)
Diversification : Co revenue from Generic API was at 95% & Synthesis was at 5% in FY16 to 54% revenue from API , 36% from Formulation & 10% from CDMO by FY20.
Co has done extremely well to diversify the business within 4 year.
(2/11)
Co has done extremely well to diversify the business within 4 year.
(2/11)
Generic API:
1. Contribute more than 50% revenue & major products
are : ARV , Hepatits-C , oncology , other API which include
cardiovascular, anti-asthmatic, gastroenterology API.
2. Other API growth are at highest level 207% yoy.
3. ARV was in de-growth for 3qtr..
(3/11)
1. Contribute more than 50% revenue & major products
are : ARV , Hepatits-C , oncology , other API which include
cardiovascular, anti-asthmatic, gastroenterology API.
2. Other API growth are at highest level 207% yoy.
3. ARV was in de-growth for 3qtr..
(3/11)
